A future of AI-driven personalized care for people with multiple sclerosis

dc.contributorAalto-yliopistofi
dc.contributorAalto Universityen
dc.contributor.author, CLAIMS consortium
dc.contributor.departmentDepartment of Neuroscience and Biomedical Engineeringen
dc.date.accessioned2024-09-19T15:33:21Z
dc.date.available2024-09-19T15:33:21Z
dc.date.issued2024-08-19
dc.descriptionPublisher Copyright: Copyright © 2024 Praet, Anderhalten, Comi, Horakova, Ziemssen, Vermersch, Lukas, van Leemput, Steppe, Aguilera, Kadas, Bertrand, van Rampelbergh, de Boer, Zingler, Smeets, Ribbens and Paul.
dc.description.abstractMultiple sclerosis (MS) is a devastating immune-mediated disorder of the central nervous system resulting in progressive disability accumulation. As there is no cure available yet for MS, the primary therapeutic objective is to reduce relapses and to slow down disability progression as early as possible during the disease to maintain and/or improve health-related quality of life. However, optimizing treatment for people with MS (pwMS) is complex and challenging due to the many factors involved and in particular, the high degree of clinical and sub-clinical heterogeneity in disease progression among pwMS. In this paper, we discuss these many different challenges complicating treatment optimization for pwMS as well as how a shift towards a more pro-active, data-driven and personalized medicine approach could potentially improve patient outcomes for pwMS. We describe how the ‘Clinical Impact through AI-assisted MS Care’ (CLAIMS) project serves as a recent example of how to realize such a shift towards personalized treatment optimization for pwMS through the development of a platform that offers a holistic view of all relevant patient data and biomarkers, and then using this data to enable AI-supported prognostic modelling.en
dc.description.versionPeer revieweden
dc.format.extent10
dc.format.mimetypeapplication/pdf
dc.identifier.citationCLAIMS consortium 2024, ' A future of AI-driven personalized care for people with multiple sclerosis ', FRONTIERS IN IMMUNOLOGY, vol. 15, 1446748, pp. 1-10 . https://doi.org/10.3389/fimmu.2024.1446748en
dc.identifier.doi10.3389/fimmu.2024.1446748
dc.identifier.issn1664-3224
dc.identifier.otherPURE UUID: 58b4947f-39c9-44d5-bffb-3fa636aec421
dc.identifier.otherPURE ITEMURL: https://research.aalto.fi/en/publications/58b4947f-39c9-44d5-bffb-3fa636aec421
dc.identifier.otherPURE LINK: http://www.scopus.com/inward/record.url?scp=85203000845&partnerID=8YFLogxK
dc.identifier.otherPURE FILEURL: https://research.aalto.fi/files/158726607/A_future_of_AI-driven_personalized_care_for_people_with_multiple_sclerosis.pdf
dc.identifier.urihttps://aaltodoc.aalto.fi/handle/123456789/130885
dc.identifier.urnURN:NBN:fi:aalto-202409196432
dc.language.isoenen
dc.publisherFrontiers Media
dc.relation.ispartofseriesFRONTIERS IN IMMUNOLOGY
dc.relation.ispartofseriesVolume 15, pp. 1-10
dc.rightsopenAccessen
dc.subject.keywordAI
dc.subject.keyworddata
dc.subject.keyworddiagnosis
dc.subject.keyworddisease progression
dc.subject.keywordmultiple sclerosis
dc.subject.keywordpersonalized medicine
dc.subject.keywordprognosis
dc.titleA future of AI-driven personalized care for people with multiple sclerosisen
dc.typeA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessäfi
dc.type.versionpublishedVersion

Files